David M. Nanus
0000-0003-3514-2976
Publication & Citation Trends
Publications
0 total
796 Differential Expression of ASCL1, NEUROD1, and YAP1 in Neuroendocrine Prostate Cancer (NEPC) Suggests Potential Molecular Subtypes
Cited by 0
Semantic Scholar
Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.
Cited by 0
Semantic Scholar
Abstract CT305: Fractionated (dose dense) and multiple dose PSMA-targeted alpha emitter 225Ac-J591 for advanced prostate cancer: Final primary and secondary outcomes
Cited by 0
Semantic Scholar
Patient-reported outcomes (PRO) from a dose-escalation and expansion trial of fractionated and multiple-cycle PSMA-targeted alpha radionuclide 225 Ac-J591.
Cited by 0
Semantic Scholar
Abstract NG10: First-in-class dual AR/AR-V7 molecular glue degraders targeting the undruggable N-terminal domain to overcome therapeutic resistance in prostate cancer
Cited by 0
Semantic Scholar
PD13-06 225Ac-J591 PSMA-TARGETED RADIONUCLIDE THERAPY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH PRIOR 177Lu-PSMA THERAPY
Cited by 0
Semantic Scholar
Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic Vulnerabilities
Cited by 1
Semantic Scholar
PD13-07 PSMA-TARGETED ACTINIUM-225 THERAPY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: COMPARATIVE OUTCOMES BETWEEN MONOTHERAPY VS. COMBINATION THERAPY
Cited by 0
Semantic Scholar
Research Topics
Prostate Cancer Treatment and Research
(489)
Radiopharmaceutical Chemistry and Applications
(201)
Cancer Genomics and Diagnostics
(117)
Renal cell carcinoma treatment
(88)
Cancer, Lipids, and Metabolism
(70)
Affiliations
Northwestern University
Fox Chase Cancer Center
Roswell Park Comprehensive Cancer Center
Deaconess Hospital
Cleveland Clinic